Abstract
Primary Amoebic Meningoencephalitis (PAM) is a severe and often fatal infection caused by the free-living amoebae Naegleria fowleri. This condition typically results from exposure to contaminated warm freshwater/inadequately treated recreational water/or ablution/nasal irrigation with contaminated water. The management of PAM is hindered by the absence of effective treatment coupled with challenges in early diagnosis. This review explores emerging patents that could be utilized for the treatment, diagnosis of PAM, as well as water treatment. Recent patents from the past five years, along with research and innovations are reviewed and categorized into therapeutic agents, water treatment technologies, and diagnostic methods. It is hoped that collaboration and awareness between pharmaceutical companies, water industries, and academic institutions is essential for advancing effective strategies against this severe central nervous system pathogen.
Original language | English |
---|---|
Journal | Pharmaceutical Patent Analyst |
Early online date | 3 Feb 2025 |
DOIs | |
Publication status | E-pub ahead of print - 3 Feb 2025 |
Keywords
- brain eating amoebae
- central nervous system infections
- Naegleria fowleri
- patents
- primary amebic meningoencephalitis
ASJC Scopus subject areas
- Pharmaceutical Science
- Drug Discovery